We are live on ! Find out more
XBIO icon

Xenetic Biosciences
XBIO

3 hedge funds and large institutions have $1.51M invested in Xenetic Biosciences in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more capital invested

Capital invested by funds: $1.44M → $1.51M (+$67K)

0% less ownership

Funds ownership: 0.03% → 0.03% (-0%)

25% less funds holding

Funds holding: 4 → 3 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$4.25K

Top Sellers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
-$19K
2
UBS Group
UBS Group
Switzerland
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
1
Royal Bank of Canada
Ontario, Canada
$1.47M – – –
Morgan Stanley
2
Morgan Stanley
New York
$27K – – –
TRCT
3
Tower Research Capital (TRC)
New York
$5K +$4.25K +8 New
Barclays
4
Barclays
United Kingdom
– -$19K -37 Closed
UBS Group
5
UBS Group
Switzerland
– -$1K -2 Closed

XBIO Hedge Fund Activity: Q1 2017 in Review

3 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q1 2017, worth a combined $1.51M — up 4.7% from $1.44M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of XBIO and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $4.25K. The largest seller was Barclays, exiting entirely with an estimated $19K sold.

  • 3 institutional investors held Xenetic Biosciences (XBIO) as of Q1 2017, down from 4 in Q4 2016.
  • Funds reported $1.51M of Xenetic Biosciences stock for Q1 2017, up 4.7% quarter-over-quarter.
  • 1 fund opened new Xenetic Biosciences positions in Q1 2017 and 2 closed out, a net change of -1 holder.
  • The largest Xenetic Biosciences buyer in Q1 2017 was Tower Research Capital (TRC), an estimated $4.25K added.
  • The largest Xenetic Biosciences seller in Q1 2017 was Barclays, an estimated $19K sold.

Based on aggregated 13F filings for Q1 2017.